Maitreya Medicare LimitedQ2 FY27 Results & Financial Update
Maitreya Medicare Limited: Q2 FY27 consolidated results and company financials – revenue ₹23.68 Cr, PAT ₹-0.94 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Maitreya Medicare price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Maitreya Medicare Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended September 30, 2026 (Q2 FY27), Maitreya Medicare reported consolidated revenue from operations of INR 23.68 crore and total consolidated income of INR 24.02 crore.
The company incurred a consolidated net loss after tax (PAT) of INR 0.94 crore for the quarter, alongside a consolidated profit before tax (PBT) of negative INR 0.43 crore.
Total expenses for the quarter stood at INR 24.48 crore, driven by high operating outlays including other expenses of INR 14.29 crore and employee benefit expenses of INR 3.45 crore.
Finance costs for the quarter were recorded at INR 1.04 crore, while depreciation and amortisation expenses amounted to INR 1.20 crore.
Tax expenses for the quarter totalled INR 0.51 crore, comprising current tax, deferred tax of INR 0.19 crore, and minimum alternate tax (MAT) provisions.
Basic and diluted earnings per share (EPS) for the quarter stood at negative INR 1.38 on a face value of INR 10 per share.
01 · Business model
What does Maitreya Medicare do?
Maitreya Medicare Limited operates multi-superspeciality hospitals and research centres, delivering professional healthcare services and medical products primarily in Gujarat, India.
The company's primary revenue engine stems from clinical treatments, surgeries, diagnostic services, pharmaceutical dispensing, and related healthcare operations.
Maitreya delivers its medical offerings through its corporate setup in Surat as well as expanding subsidiaries, targeting local and regional patients seeking advanced multi-superspeciality care.
The corporate structure includes wholly-owned subsidiary Maitreya Lifescience Private Limited alongside subsidiaries Maitreya Hospital Private Limited and Tulip Agility Private Limited.
02 · Historical context
What shaped the business before this quarter
Previously, the company raised funds via an initial public offer (IPO) consisting of 18,16,000 equity shares at INR 10 each at a premium, listing on the Emerge Platform of the National Stock Exchange of India on November 7, 2023.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹23.68 Cr |
| Total income | ₹24.02 Cr |
| Profit before tax | ₹-0.43 Cr |
| Profit after tax | ₹-0.94 Cr |
| EPS | ₹-1.38 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -4.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -1.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.34 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations of INR 23.68 crore was generated entirely through the provision of healthcare services and related medical products, reflecting unified operations under a single reportable segment.
What drove margins
Other expenses formed the largest cost block at INR 14.29 crore, while employee benefit expenses stood at INR 3.45 crore, placing downward pressure on operating margins.
Finance costs of INR 1.04 crore and depreciation charges of INR 1.20 crore further impacted profitability, resulting in a net loss position for the quarter.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
In accordance with AS 17, the company operates in a single reportable business segment of providing healthcare services and products, rendering separate segment reporting inapplicable.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
As per IPO proceeds utilization disclosures, the company fully utilized INR 7.50 crore allocated for making an equity investment in its subsidiary, Maitreya Hospital Private Limited, dedicated to setting up a hospital at Valsad, Gujarat.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The consolidated financial results account for operations across three subsidiaries: Maitreya Lifescience Private Limited, Maitreya Hospital Private Limited, and Tulip Agility Private Limited.
08 · Pressure points & risks
What is not going smoothly
The company reported a consolidated net loss after tax of INR 0.94 crore for Q2 FY27, reflecting ongoing operational and overhead cost pressures.
09 · Items worth noticing
The line items that can distort a quick read
The consolidated financial statement includes a prior period adjustment impact of negative INR 0.03 crore (INR -2.75 lacs) for the period.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The company fully utilized the allocated INR 5.00 crore from IPO proceeds toward funding its working capital requirements.
Capital allocation & funding
IPO proceeds of INR 1.00 crore were fully utilized toward the redemption of part of the issued Non-Convertible Redeemable Preference Shares.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory Auditor Review
The consolidated unaudited financial results for the period ended September 30, 2026, were reviewed by statutory auditors Saherwala & Co. and approved by the Board of Directors on October 22, 2026.
12 · Key Q&A
The quarter, answered directly
What does Maitreya Medicare do?
Maitreya Medicare Limited operates multi-superspeciality hospitals and research centres, delivering professional healthcare services and medical products primarily in Gujarat, India.
What is the clearest takeaway from Q2 FY27?
For the quarter ended September 30, 2026 (Q2 FY27), Maitreya Medicare reported consolidated revenue from operations of INR 23.68 crore and total consolidated income of INR 24.02 crore.
What drove revenue or demand?
Revenue from operations of INR 23.68 crore was generated entirely through the provision of healthcare services and related medical products, reflecting unified operations under a single reportable segment.
What mattered most for margins or profitability?
Other expenses formed the largest cost block at INR 14.29 crore, while employee benefit expenses stood at INR 3.45 crore, placing downward pressure on operating margins.
What changed operationally beyond the headline numbers?
As per IPO proceeds utilization disclosures, the company fully utilized INR 7.50 crore allocated for making an equity investment in its subsidiary, Maitreya Hospital Private Limited, dedicated to setting up a hospital at Valsad, Gujarat.
What are the main pressure points disclosed for the quarter?
The company reported a consolidated net loss after tax of INR 0.94 crore for Q2 FY27, reflecting ongoing operational and overhead cost pressures.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Valsad Facility Progress: Monitor the operational rollout and patient inflow milestones at the newly funded hospital project in Valsad, Gujarat.
- 02
Profitability Turnaround: Track future quarterly disclosures to assess cost optimization and margin recovery toward achieving net profitability.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.